Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

FreeStyle Libre 2 Continuous Glucose Monitor

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Berlin, Germany—February 20–23, 2019

FreeStyle Libre 2 Continuous Glucose Monitor

Abbott's FreeStyle Libre 2 CGM picks up Medicare coverage

Abbott Releases the FreeStyle Libre 2 iCGM - Children with Diabetes

Freestyle Libre 2 - Continuous Glucose Monitoring System

Freestyle Libre 2 - Continuous Glucose Monitoring System

FreeStyle Libre 2 System

Freestyle Libre 2 - Continuous Glucose Monitoring System

Healthy Living Now Providing the Abbott Freestyle Libre to Medicare Members — Healthy Living Medical Supply